Heraeus Medical Components is acquiring conductive polymer materials maker Biotectix.
The deal, announced yesterday, will allow Heraeus to boost its medical electrode coating capabilities. Better electrode coatings equal better performance of sensing and stimulation electrodes used in diagnostic and therapeutic medical devices.
Financial terms of the deal were not disclosed.
“We constantly work with our medical device customers to find ways to make products less invasive with added functionality for improved performance and at a lower cost,” Nicolas Guggenheim, president of Heraeus Medical Components, said in a news release.
“The medical electrode is a critical part of the equation and Heraeus is a world leader in stimulation electrodes,”Guggenheim said. “Biotectix has truly been an innovator with their electro-conductive polymer solutions. Combining our electrode expertise with Biotectix opens up new possibilities for us to deliver new solutions for our customers.”
Founded in 2007, Biotectix (Richmond, Calif.) is best known for its development of Amplicoat and Tecticoat, two electro-conductive polymer coatings with a reputation for high durability. Amplicoat is able to enhance electrical communication between human tissue and medical device electrodes inside the human body, according to Heraeus. Tecticoat provides electrical conductivity, shielding and electrostatic dissipation for applications that come in contact with the skin.
Heraeus Medical Components is a St. Paul, Minn.–based subsidiary of the Hanau, Germany–based Heraeus Group.